Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Comabella

Showing results (121-130 of 263) with videos related to

Pageof 27
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2017
Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patientsJordi Río, Àlex Rovira, Mar Tintoré, et al.
Scientific Reports|October 21, 2017
Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple SclerosisÁgueda Martínez-Barriocanal, Andrea Arcas-García, Miriam Magallon-Lorenz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2018
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosisNicolas Fissolo, Laura Cervera-Carles, Luisa María Villar Guimerans, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 10, 2017
Metabolomic signatures associated with disease severity in multiple sclerosisPablo Villoslada, Cristina Alonso, Ion Agirrezabal, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2012
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur, Mar Tintoré, Angela Vidal-Jordana, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 13, 2021
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MSNicolás Fissolo, Clara Matute-Blanch, Mohamoud Osman, et al.
Neurology|April 30, 2013
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosisManuel Comabella, Ana B Caminero, Sunny Malhotra, et al.
Biomarkers in Medicine|August 16, 2014
Circulating microparticles reflect treatment effects and clinical status in multiple sclerosisMatías Sáenz-Cuesta, Haritz Irizar, Tamara Castillo-Triviño, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2015
Should we systematically test patients with clinically isolated syndrome for auto-antibodies?Laura Negrotto, Carmen Tur, Mar Tintoré, et al.
Journal of Neuroimmunology|May 6, 2014
No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosisFranca R Guerini, Mario Clerici, Rachele Cagliani, et al.
Pageof 27

Showing results (121-130 of 263) with videos related to

Sort By:
Pageof 27
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2017
Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patientsJordi Río, Àlex Rovira, Mar Tintoré, et al.
Scientific Reports|October 21, 2017
Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple SclerosisÁgueda Martínez-Barriocanal, Andrea Arcas-García, Miriam Magallon-Lorenz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 10, 2018
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosisNicolas Fissolo, Laura Cervera-Carles, Luisa María Villar Guimerans, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 10, 2017
Metabolomic signatures associated with disease severity in multiple sclerosisPablo Villoslada, Cristina Alonso, Ion Agirrezabal, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2012
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur, Mar Tintoré, Angela Vidal-Jordana, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 13, 2021
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MSNicolás Fissolo, Clara Matute-Blanch, Mohamoud Osman, et al.
Neurology|April 30, 2013
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosisManuel Comabella, Ana B Caminero, Sunny Malhotra, et al.
Biomarkers in Medicine|August 16, 2014
Circulating microparticles reflect treatment effects and clinical status in multiple sclerosisMatías Sáenz-Cuesta, Haritz Irizar, Tamara Castillo-Triviño, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2015
Should we systematically test patients with clinically isolated syndrome for auto-antibodies?Laura Negrotto, Carmen Tur, Mar Tintoré, et al.
Journal of Neuroimmunology|May 6, 2014
No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosisFranca R Guerini, Mario Clerici, Rachele Cagliani, et al.
Pageof 27